Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Atara Bio­ther­a­peu­tics said Tues­day that it plans to sub­mit its T cell im­munother­a­py for ap­proval in the US next year.

The ther­a­py was ap­proved last year in the EU, where it is mar­ket­ed as Ebval­lo. For its US ap­pli­ca­tion, Atara said it can now pool piv­otal clin­i­cal tri­al da­ta from dif­fer­ent man­u­fac­tur­ing process­es af­ter dis­cussing with the FDA whether those process­es were com­pa­ra­ble.

The biotech said it ex­pects to sub­mit its mar­ket­ing ap­pli­ca­tion for tab­ele­cleu­cel as a treat­ment for Ep­stein-Barr virus-as­so­ci­at­ed post-trans­plant lym­pho­pro­lif­er­a­tive dis­ease in the sec­ond quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER